With just enough cash to stay afloat until the first quarter, Midatech is linking up with US-based, Canada-listed Bioasis to create a new rare disease player, Biodexa.

The year to date has been a depressing period for initial public offerings, especially in Europe, but the Madrid-based epigenetics specialist is evaluating whether to head west and list in the US.

A market leader in opioid addiction, Indivior is expanding into the cannabis abuse space which is increasing exponentially due to widespread legalization of recreational use for the drug.